Molecular Cell

CellPress

Review

Exploiting dynamic enhancer landscapes to decode macrophage and microglia phenotypes in health and disease

Ty D. Troutman,[1,4,5] Eric Kofman,[2,3] and Christopher K. Glass[1,2,6]
[1]Department of Medicine, University of California, San Diego, San Diego, CA, USA
[2]Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA, USA
[3]Bioinformatics and Systems Biology Graduate Program, University of California, San Diego, San Diego, CA, USA
[4]Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
[5]Center for Inflammation and Tolerance, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
*Correspondence: ckg@ucsd.edu
https://doi.org/10.1016/j.molcel.2021.08.004

SUMMARY

The development and functional potential of metazoan cells is dependent on combinatorial roles of transcriptional enhancers and promoters. Macrophages provide exceptionally powerful model systems for investigation of mechanisms underlying the activation of cell-specific enhancers that drive transitions in cell fate and cell state. Here, we review recent advances that have expanded appreciation of the diversity of macrophage phenotypes in health and disease, emphasizing studies of liver, adipose tissue, and brain macrophages as paradigms for other tissue macrophages and cell types. Studies of normal tissue-resident macrophages and macrophages associated with cirrhosis, obese adipose tissue, and neurodegenerative disease illustrate the major roles of tissue environment in remodeling enhancer landscapes to specify the development and functions of distinct macrophage phenotypes. We discuss the utility of quantitative analysis of environment-dependent changes in enhancer activity states as an approach to discovery of regulatory transcription factors and upstream signaling pathways.

INTRODUCTION

Macrophages are central players in the immune system whose roles in maintaining homeostasis and tissue repair are dependent on their specialized abilities in pattern recognition, phagocytosis, autophagy, and secretion of regulatory chemokines and cytokines. Both resident and recruited macrophages protect the host from pathogen infection and can be involved in chronic inflammation unrelated to infection (Okabe and Medzhitov, 2016; Wynn et al., 2013). Ligation of pattern-recognition receptors, such as TLR4 by lipopolysaccharide (LPS), activates downstream signaling cascades that cause extensive changes in the epigenetic landscape and gene expression (Glass and Natoli, 2016). Until recently, studying the macrophage-specific gene-expression programs involved in such activity at the cellular and molecular levels relied on in vitro model systems based on the generation of primary macrophage-like cells from bone marrow progenitor cells, peritoneal exudates, or circulating monocytes (Lawrence and Natoli, 2011). Although these model systems remain highly valuable for mechanistic studies, they do not capture the full spectrum of macrophage functions and diversity in vivo. Recent advances enabling the tracing, isolation, and analysis of single cells are catalyzing rapid progress in defining tissue-specific macrophage cell populations in health and disease (Bandura et al., 2009; Becher et al., 2014; David et al., 2016; Giladi and Amit, 2018; Grindberg

et al., 2013). These technologies are providing new insights into the developmental trajectories of macrophages, adding nuance to simplified models of how resident and recruited macrophage phenotypes change during inflammatory events and raising new questions as to how various macrophage populations acquire tissue-specific identities and functions. Parallel advances in high-throughput genomic assays have also enabled the extension of genome-wide studies of transcriptional enhancers and promoters of resident and recruited macrophage populations in tissues (Gosselin et al., 2014, 2017; Lavin et al., 2014; Sakai et al., 2019; Seidman et al., 2020; Soucie et al., 2016). These approaches have been used to infer key transcription factors (TFs) and upstream regulatory pathways responsible for context-dependent gene expression in vivo. The combination of single-cell isolation and sorting approaches with high-throughput epigenetic assays has allowed for an increasingly fine-grained understanding of the mechanisms underlying macrophage and related myeloid cell diversity in health and disease. Here, we review recent advances in the field, emphasizing studies of liver, adipose tissue, and brain macrophages as paradigms for other tissues and cell types.

BACKGROUND

Lineage tracing studies in mice have demonstrated that during early fetal development, hematopoietic progenitor cells (HPCs)

Figure 1. Nature and nurture of tissue-resident macrophages
Yolk-sac-derived hematopoietic progenitor cells (HPCs) engraft tissues during early fetal development. This process continues after transition of hematopoiesis from the yolk sac to the fetal liver, resulting in all tissues containing embryonically derived, resident macrophage populations at the time of birth. Each tissue provides a distinct environmental context that dictates the resulting resident macrophage phenotype, exemplified by brain microglia, liver Kupffer cells, and adipose tissue macrophages. Microglia are self-renewing and remain exclusively HPC derived throughout life in the healthy brain. Resident macrophages are replaced to variable extents in other tissues over time by HSC-derived monocytes that exhibit convergent, but non-identical, patterns of differentiation with the embryonically derived macrophages.

from the yolk sac migrate into tissues and acquire tissue-specific macrophage phenotypes, exemplified by brain microglia and skin Langerhans cells (Ginhoux and Guilliams, 2016; Gomez Perdiguero et al., 2015; McGrath et al., 2015; Schulz et al., 2012) (Figure 1). Transition of hematopoiesis from the yolk sac to the fetal liver results in a second wave of HPC-derived cells entering tissues and differentiating into macrophages, largely replacing yolk-sac-derived macrophages in tissues, such as liver and lung. After the establishment of definitive hematopoiesis in the bone marrow, hematopoietic stem cell (HSC)-derived monocytes contribute to and, in some cases, ultimately, replace fetal macrophage populations under homeostatic conditions in tissues, such as the heart (Epelman et al., 2014). Pathological conditions, including trauma, infection, and a multitude of chronic diseases, alter the phenotypes of resident macrophages and induce the recruitment of monocyte-derived cells that acquire context-specific macrophage phenotypes (e.g., (Bennett and Bennett, 2020; Lee and Olefsky, 2021; Orme and Basaraba, 2014; Wen et al., 2021; Zaidi et al., 2021)).

Microarray and RNA sequencing analyses of major tissue-resident populations of macrophages revealed a high degree of diversity of gene expression superimposed on a core program of macrophage gene expression dedicated to phagocytosis and immune functions (Gautier et al., 2012; Gosselin et al., 2014; Hammond et al., 2019; Hickman et al., 2013; Lavin et al., 2014;

Mass et al., 2016). Tissue-specific patterns of gene expression are generally linked to corresponding tissue-specific developmental and homeostatic functions. For example, microglia monitor synapses and are important sources of growth factors for neurons (Bartels et al., 2020; Hammond et al., 2018; Prinz et al., 2019), whereas Kupffer cells in the liver have roles in iron homeostasis and are involved in detoxifying gut-derived LPS (Krenkel and Tacke, 2017). Recent studies of mouse and human samples support the concept that distinct macrophage phenotypes arise as the consequence of instructive roles of the tissue environment acting on an epigenetic landscape determined by the cell of origin (i.e., yolk sac/fetal liver-derived HPCs versus bone-marrow-derived HSCs) (Gosselin et al., 2014, 2017; Lavin et al., 2014) (Figure 1). The recent application of single-cell sequencing and high-dimensional flow cytometry has significantly expanded appreciation of the diversity of macrophage phenotypes resident in tissues under homeostatic and disease contexts in both human subjects and mouse models (Bassler et al., 2019; David et al., 2016; Giladi and Amit, 2018; Hammond et al., 2019; Jaitin et al., 2019; Li et al., 2019; Masuda et al., 2019), implying a corresponding diversity in instructive niches. Although substantial progress has been made in identifying environmental signals, receptors, and TFs that have essential roles in establishing specific phenotypes, recent studies highlight major knowledge gaps for even the most intensively studied

Molecular Cell
Review

CellPress

macrophage populations, exemplified by brain microglia, liver Kupffer cells, and adipose tissue macrophages. An example is provided by the discovery that the pattern recognition receptor Trem2 is upregulated in each of these cell types in many disease contexts and contributes to their disease-associated phenotypes. Many fundamental questions remain as to the molecular mechanisms by which Trem2 and other signaling pathways determine the identities and functions of resident and recruited macrophages in health and disease. Answering these questions will be a pre-requisite to developing rational methods to target macrophages for therapeutic purposes.

Acquisition of macrophage identity and signal-dependent responses

Peritoneal macrophages, bone-marrow-derived macrophages, and monocyte-derived macrophages can be maintained in tissue culture and retain numerous "core" macrophage functions, including phagocytosis and responses to diverse pathogen and host-derived signals, such as bacterial LPS and type I interferons (IFNs), respectively. Accordingly, these systems have been used extensively to investigate transcriptional mechanisms underlying macrophage identity and function (Lawrence and Natoli, 2011). Cell-specific gene expression is controlled by the concerted actions of promoters and transcriptional enhancers (Furlong and Levine, 2018; Heinz et al., 2013; Levine, 2010). Although promoters are the essential sites of transcriptional initiation of mRNAs, they do not provide sufficient information to direct the diverse range of gene expressions required for cellular development and cell-specific responses to internal and external signals. This additional specificity is largely provided by distal enhancers, which are the genomic regions that are the major binding sites of lineage-determining TFs. Studies of mouse macrophages *in vitro* provided evidence that most enhancers are selected by relatively simple combinations of lineage-determining transcription factors (LDTFs), including PU.1 and members of the C/EBP, AP-1, and RUNX families (Ghisletti et al., 2010; Heinz et al., 2010) (Figure 2A). These factors collaborate with each other and with dozens of other TFs to bind to closely spaced DNA recognition motifs at tens of thousands of locations throughout the genome (Link et al., 2018). These binding events are associated with the displacement of nucleosomes and establish "primed enhancers" that provide access to broadly expressed signal-dependent transcription factors (SDTFs), exemplified by nuclear receptors and nuclear factor κB (NF-κB) (Figure 2B). The mechanisms by which the binding of LDTFs result in nucleosome displacement remain poorly understood, but they presumably require the actions of chromatin-remodeling factors. Intriguingly, members of the IFN regulatory factor (IRF) family of TFs provide examples of LDTFs, collaborating TFs, and SDTFs. For example, high levels of IRF8 expression are required for the developmental decision of myeloid cells to differentiate into monocytes, rather than neutrophils (Murakami et al., 2021). IRF1, IRF2, and IRF4 are constitutively expressed in macrophages, and IRF motif mutations reduce the nearby binding of PU.1, C/EBP, and AP-1 factors, consistent with required collaborative interactions (Link et al., 2018). IRF3 activity is strongly induced after TLR4 ligation (Takeda and Akira, 2004), and IRF-binding motifs are strongly enriched in TLR4-activated en-

hancers (Ghisletti et al., 2010). The recruitment of signal-dependent factors, such as nuclear receptors, NF-κB, and IRF3, to cell-specific enhancers that are first hierarchically primed by distinct combinations of lineage determining factors, thereby, results in cell-specific responses to a common signal. An important subset of primed enhancers exhibits a "poised-repressed" state because of the recruitment of transcriptional co-repressors (Figure 2A). Examples of poised/repressed enhancers are provided by enhancers occupied by RbpJ or unliganded nuclear receptors that recruit the co-repressor NCoR (Li et al., 2013; Sakai et al., 2019). This "collaborative-hierarchical" model of enhancer selection and function provides a conceptual basis for understanding macrophage diversification *in vivo*, as discussed further below.

Responses of macrophages to LPS provide one of the major paradigms for investigation of signal-dependent gene expression. Ligation of TLR4 by LPS initiates signaling through MyD88- and TRIF-dependent pathways that result in the rapid activation of NF-κB, IRF. and AP-1 TFs (Kawai and Akira, 2011). As alluded to above, these factors primarily bind to a pre-existing, cell-specific regulatory landscape (Barish et al., 2010; Fonseca et al., 2019; Ghisletti et al., 2010; Kaikkonen et al., 2013), frequently associated with promoters in which RNA polymerase II is already recruited in a "paused" configuration (Adelman et al., 2009; Gilchrist et al., 2010; Gupte et al., 2013). Three-dimensional chromatin-conformation capture assays demonstrated pre-existing connectivity between enhancers and promoters required for maximal responses of LPS-responsive genes (Cuartero et al., 2018; Link et al., 2018), reinforcing the concept of a transcriptional network that is poised for rapid activation. The immediate consequence of TF binding to enhancers and promoters is the secondary recruitment of an intermediary set of co-activators that have key roles in modifying chromatin and mediating recruitment and/or conversion of paused RNA polymerase to an active, elongating form. These include chromatin remodeling complexes (SWI/SNF) (Gatchalian et al., 2020; Lai et al., 2009), complexes with histone acetyl transferase activity (e.g., CBP and p300), histone methyltransferases (e.g., MLL proteins [Kaikkonen et al., 2013]), histone demethylases (e.g., JMJD3 [De Santa et al., 2009]), bromodomain readers of histone acetylation (e.g., Brd4 [Nicodeme et al., 2010]), and kinase activity (e.g., pTEFb) (Hargreaves et al., 2009). The concerted actions of these complexes at enhancers result in dissociation of the negative elongation factor (NELF) complex, release of PolII from its promoter-paused position, and rapid induction of gene transcription (Adelman et al., 2009). Many of the key drivers of inflammatory responses to TLR4 ligation in macrophages are associated with dense arrays of enhancers (Hah et al., 2015), referred to as super enhancers (Whyte et al., 2013). Recent studies indicate that LPS treatment of macrophages leads to a substantial increase in the genomic binding sites of Brd4. Myeloid-specific deletion of Brd4 results in a dramatic reorganization of the macrophage super-enhancer landscape and reduced activation of a subset of TLR4-responsive genes (Dey et al., 2019). Intriguingly, macrophages compensate for Brd4 deletion by establishing new super enhancers that mitigate the overall effect on

Figure 2. Mechanisms driving the selection and activation of signal-dependent, macrophage-specific enhancers

(A) Combinations of lineage-determining transcription factors (LDTFs) with the ability to interact with their DNA-recognition motifs in the context of closed chromatin initiate enhancer selection through collaborative binding interactions with each other and with dozens of other co-expressed collaborative transcription factors (CTFs). These binding interactions establish regions of open chromatin that enable access to broadly expressed, signal-dependent transcription factors (SDTFs), such as NF-κB (left branch of the pathway). Activation of NF-κB by LPS results in its binding to poised enhancers containing κB-recognition motifs, resulting in enhancer activation and control of target genes in a macrophage-specific manner. A variation of this pathway involves collaborative interactions with active repressors, which recruit co-repressor complexes that maintain enhancers in a poised-repressed state (right branch of the pathway). Examples include RbpJ in the absence of Notch signaling and unliganded nuclear receptors, such as LXRs. Notch signaling or LXR agonists convert RbpJ and LXRs from repressors to activators, respectively, resulting in co-activator recruitment and enhancer activation.

(B) Example of activation of primed enhancers (yellow stripes) associated with the *Ptges* gene in bone-marrow-derived macrophages. Treatment with a TLR4 agonist leads to p65 (NF-κB) binding at genomic locations occupied by PU.1 and C/EBPβ under vehicle-treatment conditions. Binding of p65 is associated with gain of H3K27ac and increased expression of Ptges. Data from Link et al. (2018).

niche-specific instructions that were the key determinants of the terminal transcriptional state. The latter model has been reinforced by various observations. For example, entry of macrophage precursor cells into tissues during embryonic development results in rapid and progressive changes in gene expression, ultimately resolving into tissue-specific gene signatures (Mass et al., 2016). Conversely, removal of macrophages from their native tissue environment results in attenuation of these signatures.

LPS-dependent gene expression. The writing, reading, and erasing of DNA and histone modifications, thus, represent an important layer of regulation that is potentially amenable to therapeutic modification (Glass and Natoli, 2016; Seeley and Ghosh, 2017).

Niche-specific education of resident macrophage phenotypes

Macrophages reside in all major tissues, yet each subset adopts a unique transcriptional profile reflecting specialized functions adapted to its niche of residence. These observations prompted questions as to whether it was cell ontogeny or

For example, transfer of microglia and peritoneal macrophages to an *in vitro* culture environment was associated with rapid loss of a significant component of each cell's tissue-specific program of gene expression (Gosselin et al., 2014, 2017). A comparison of transcriptomes of human microglia immediately after their transfer to tissue culture environments identified ~2,400 genes that were strongly downregulated (Gosselin et al., 2017). Although genes corresponding to core macrophage functions were largely preserved, ~1,400 of the downregulated genes correspond to microglia signature genes that are upregulated in primitive mouse macrophages after their entry into the brain during fetal development. In an *in vivo*

Molecular Cell
Review

 CellPress

Figure 3. Environment-independent and environment-dependent macrophage enhancers and super enhancers
(A) Genes encoding core macrophage LDTFs are associated with super enhancers in which the component enhancers are bound by combinations of each factor, e.g., PU.1, C/EBPs, and AP-1 family members. This property is exemplified by the binding of PU.1, C/EBPβ, and cJun at a super enhancer (yellow bar) associated with the Spi1 gene, which encodes PU.1. These relationships establish a mutually reinforcing, environment-independent transcriptional network that maintains expression of core macrophage LDTFs and drives expression of core macrophage genes, such as TLRs, phagocytic receptors, etc.
(B) Many tissue-specific macrophage enhancers and super enhancers are selected and activated by combinations of TFs that are environment dependent, exemplified by Smad4 and LXRα in Kupffer cells. These factors must be expressed and active for the monocytes to acquire a Kupffer cell phenotype after Kupffer cell depletion.

demonstration of the role of tissue environment, transfer of mouse peritoneal macrophages to the alveolar air spaces resulted in upregulation of alveolar-macrophage-specific genes (Lavin et al., 2014). Likewise, in a Kupffer-cell-ablation system, the repopulating monocyte-derived macrophages adopt a

highly convergent gene expression signature (Scott et al., 2016), even though Kupffer cells in healthy animals are derived from embryonic precursors.

These findings are consistent with a major role for environment-derived signaling in directing tissue-resident macrophage phenotypic changes and further indicate that macrophage gene-expression programs are reversible and require constant reinforcement by such tissue-specific signals. Essential environmental factors have been established for some resident populations. For example, granulocyte-macrophage-colony-stimulating factor (GM-CSF) is essential for development of alveolar macrophages (Bonfield et al., 2003), retinoic acid for peritoneal macrophages (Okabe and Medzhitov, 2014), and tumor growth factor β (TGF-β) for microglia (Butovsky et al., 2014). However, although necessary, these factors are not sufficient to maintain cell-specific phenotypes *in vitro*. For example, treatment of *in vitro* microglia with TGF-β only partially activates genes that are highly TGF-β-dependent *in vivo*, indicating that the *in vivo* functions of TGF-β are dependent on interactions with other environmental signals (Gosselin et al., 2017).

Under homeostatic conditions, each tissue-resident macrophage population exhibits an overlapping, but distinct, pattern of TF expression, which underlies their tissue-specific programs of gene expression overall (Gosselin et al., 2014; Lavin et al., 2014; Mass et al., 2016). The myeloid and B cell lineage-determining factor PU.1 is universally expressed, consistent with its requirement for all macrophage populations (Fisher and Scott, 1998). Members of the AP-1, C/EBP, MAF, IRF, RUNX, and TFE/MITF families are also broadly expressed across tissue-resident populations and function in combination with PU.1 to establish expression of a core set of macrophage genes, including *Csf1r* and genes encoding cytokine receptors, complement and complement receptors, pattern-recognition receptors, phagocytic receptors, and Fcγ receptors (Mass et al., 2016). Chromatin immunoprecipitation sequencing (ChIP-seq) experiments indicate that the genes encoding most of these lineage-determining TFs reside in the vicinity of super enhancers that are occupied by combinations of each other (Gosselin et al., 2014; Link et al., 2018). For example, the PU.1, C/EBPB, and cJun super enhancers are each occupied by PU.1, C/EBPβ, and cJun. These relationships are likely to establish a set of self-reinforcing transcriptional networks that results in a stable, environment-independent core-macrophage phenotype, exemplified by the combinatorial binding of PU.1, C/EBPβ, and cJun at the super enhancer associated with the *Spi1* gene, which encodes PU.1 (Figure 3A).

Diversification of TF expression and function is observed shortly after macrophage progenitor cells enter distinct tissue environments during development, which continues concomitant with tissue differentiation (Mass et al., 2016; Matcovitch-Natan et al., 2016). Examples of TFs that are highly expressed in specific macrophage subsets in comparison with other tissue-resident macrophages include SALL1 in microglia, LXRα in Kupffer cells, PPARγ in alveolar macrophages, and GATA6 in peritoneal macrophages (Lavin et al., 2014; Mass et al., 2016; Matcovitch-Natan et al., 2016). Consistent with this differential pattern of TF expression, the enhancer landscapes exhibit corresponding cell-specific differences, with DNA motif enrichment

analysis generally recovering the recognition elements for sub-set-specific factors. For example, GATA motifs are uniquely recovered from the set of peritoneal macrophage-specific enhancers, PPARγ motifs from alveolar macrophage enhancers, and LXR motifs from Kupffer-cell-specific enhancers (Gosselin et al., 2014; Lavin et al., 2014; Sakai et al., 2019).

In contrast to TFs establishing core programs of macrophage gene expression, expression of many of the TFs driving tissue-specific macrophage phenotypes require constant environmental input as evidenced by the loss of expression when cells are transferred to an *in vitro* environment. This pattern is exemplified by rapid downregulation of *Gata6* in peritoneal macrophages and *Sall1* in microglia after *in vitro* culture and is accompanied by a corresponding loss of active enhancers dependent on these factors (Gosselin et al., 2014, 2017). Within peritoneal macrophages, *Gata6* expression is controlled by environmentally derived retinoic acid (Okabe and Medzhitov, 2014), which acts on retinoic acid receptors to transcriptionally regulate enhancers controlling *Gata6* expression (Gosselin et al., 2014). In microglia, TGF-β signaling regulates the expression of SMAD proteins that are putative drivers of the TGF-β-dependent expression of *Sall1* (Butovsky et al., 2014). These observations suggest a model in which environmental factors regulate the activities of signal-dependent TFs to initially induce specific macrophage-lineage-determining factors, which they subsequently interact with to drive the selection of new enhancers that specify context-specific gene expression.

The loss of tissue-specific macrophage gene expression patterns *in vitro* represents a significant limitation of *in vitro* systems to model homeostatic and disease phenotypes. This limitation also applies to macrophages derived from induced pluripotent stem cells (iPSCs) *in vitro*. For example, the generation of microglia-like cells from iPSCs *in vitro* (Abud et al., 2017; Muffat et al., 2016) resembles primary microglia that have been transferred to a tissue culture environment (Gosselin et al., 2017; Hasselmann et al., 2019). Efforts to restore primary microglia phenotypes *in vitro* or induce a more *in-vivo*-like phenotype of iPSC-derived microglia *in vitro* by the addition of putative environmental signals, co-culturing with neurons and astrocytes, or incorporating into neuron/astrocyte organoids result in a limited transition toward the gene-expression pattern observed in microglia *in vivo*. An important recent advance is the development of systems in which human iPSC-derived HPCs are engrafted into the brains of immunodeficient newborn mice in which the mouse gene encoding CSF-1 is replaced by the human CSF-1 gene. The engrafted HPCs differentiate into microglia that morphologically and transcriptionally resemble *ex vivo* human microglia (Hasselmann et al., 2019; Mancuso et al., 2019; Svoboda et al., 2019), providing a powerful experimental system for investigation of environment-dependent gene expression and human microglia differentiation going forward.

Contribution of cell ontogeny to macrophage specification

Because tissue-resident macrophages are derived from progenitor cells that are distinct from those that give rise to parenchymal cells, a major question is the extent to which ultimate macrophage phenotypes are dependent on their developmental ori-

gins. One experimental approach is to deplete the endogenous population of macrophages, creating an empty niche that leads to replacement by circulating HSC-derived cells. This approach has been extensively applied to mouse brain microglia, in which a variety of methods, including diphtheria toxin ablation and CSF1 receptor inhibition, have been used to deplete the resident HPC-derived microglia populations and to characterize the molecular phenotypes of HSC-derived cells that replace them (Bennett et al., 2018; Cronk et al., 2018; Shemer et al., 2018; Xu et al., 2020). In all cases examined, graft-derived cells acquire microglia characteristics, including ramified morphology and expression of numerous microglia-specific genes. However, even after prolonged residence in the CNS, engrafted cells derived from HSCs exhibit hundreds of transcripts that are significantly over- or under-expressed in comparison to yolk-sac-derived macrophages, indicating a requirement for embryonic origin to acquire a microglia-specific transcriptomic signature. Consistent with this, the open chromatin environment as assessed by transposase-accessible chromatin sequencing (ATAC-seq) exhibits substantial differences (Shemer et al., 2018). Evidence that this distinct regulatory landscape is a determinant of functional potential came with the observation that HSC-derived macrophages engrafted into the brain exhibited an overlapping, but distinct, response to LPS, in comparison with embryonically derived microglia within the identical brain environment (Shemer et al., 2018).

The basis for the embryonic origin as a requirement for microglia development remains to be established. A clue is provided by the profound difference in expression of *Sall1*, a TF that is highly expressed in microglia, but not other tissue-resident macrophages (Buttgereit et al., 2016; Lavin et al., 2014; Mass et al., 2016). *Sall1* mRNA levels rapidly fall when microglia are transferred to a tissue culture environment (Gosselin et al., 2014, 2017), indicating that its expression requires constant brain environmental signals. Conditional deletion of Sall1 results in reduced expression of many microglia-specific genes and upregulation of genes associated with microglia activation, leading to an inflammatory phagocytic phenotype (Buttgereit et al., 2016). Remarkably, *Sall1* is not expressed in HSC-derived cells that engraft the brain after microglia depletion, even after long residence times (Bennett et al., 2018; Cronk et al., 2018; Shemer et al., 2018). Intriguingly, iPSC-derived hematopoietic progenitor cells, which mimic yolk-sac-derived HPCs, do not express *SALL1* during *in vitro* microglia differentiation, but upregulate *SALL1* during the process of microglia differentiation that occurs after engraftment into the mouse brain (Hasselmann et al., 2019; Mancuso et al., 2019; Svoboda et al., 2019). Thus, embryonic origin is a prerequisite to *Sall1* expression and microglia identity. The mechanisms enabling *Sall1* to be expressed in yolk-sac-derived microglia progenitor cells, but not HSC-derived cells, are unknown. One possible explanation is differential DNA methylation of the Sall1 promoter and/or enhancer elements in the progenitor cell populations, but that remains to be examined.

In the liver, it is possible to rapidly and quantitatively deplete Kupffer cells by selective expression of the diphtheria toxin receptor and administering a single dose of diphtheria toxin (Scott et al., 2016). In contrast to microglia, rapid depletion of embryonically derived Kupffer cells results in repopulation of the empty

Molecular Cell
Review

CellPress

Figure 4. Inference of transcription factors driving changes in macrophage fate and state in response to environmental signals
(A) Transitions in cell fate and state are typically driven by selection and activation of hundreds to thousands of enhancers that, in turn, regulate gene expression. This dynamic response can be quantitatively assessed at a genome-wide level using assays of open chromatin (e.g., through the use of ATAC-seq) and assays that are surrogates of enhancer activity (e.g., ChIP-seq for H3K27ac). Enriched DNA recognition motifs in the set of regulated enhancers represent binding sites for the dominant transcription factors responsible for transitions in enhancer function. The identities of these factors may enable inference of upstream signaling pathways.
(B) Enriched motifs and inferred transcription factors and upstream signaling pathways in enhancers are activated during monocyte-to-Kupffer-cell differentiation. Motifs for SMADs, RBPJ, and LXRs implicate TGF-β receptor, Notch, and LXRs as signaling pathways important for Kupffer cell differentiation. TGF-β and the Notch ligand DLL4 are potential environmental signals that are provided by sinusoidal endothelial cells. Hepatocytes produce desmosterol, which is an activating ligand for LXRs.

niche by HSC-derived cells that achieve near-complete convergence with the original Kupffer cell pattern of gene expression after 2 weeks of engraftment (Sakai et al., 2019; Scott et al., 2016). This method thereby provides a powerful model system for investigation of the mechanisms by which macrophage progenitor cells acquire tissue-specific macrophage identities. In one study, Kupffer cell loss was found to induce tumor necrosis factor (TNF)- and interleukin-1 (IL-1) receptor-dependent activation

of stellate cells and endothelial cells, resulting in the transient production of chemokines and adhesion molecules orchestrating monocyte engraftment (Bonnardel et al., 2019). Engrafted cells were found to rapidly upregulate Kupffer cell lineage-determining factors, including LXRα and Id3. Using NicheNet (Browaeys et al., 2020), a computational method for evaluating expression of potential ligand/receptor pairs, evidence was obtained supporting a model in which hepatocytes induced Id3 expression and sinusoidal endothelial cells, and stellate cells activated LXRα via expression of the Notch ligand DLL4 and bone morphogenetic proteins (BMPs) (Bonnardel et al., 2019).

In a complementary series of studies, Kupffer cells were rapidly depleted using an analogous diphtheria toxin model (Sakai et al., 2019), and temporal changes in gene expression in the newly engrafted cells were correlated with quantitative changes in open chromatin, as determined by ATAC-seq (Buenrostro et al., 2015), and enhancer activity, as assessed by ChIP-seq, for histone H3K27 acetylation (Creyghton et al., 2010). Here, the strategy was to use dynamic changes in enhancer landscapes as the basis for inferring TFs and upstream regulatory factors responsible for driving Kupffer cell differentiation. The central assumption to this approach is that each enhancer has the potential to serve as a cell-specific signal-integration hub based on the combinations of lineage-determining and signal-dependent TF binding sites it contains. Motifs enriched in newly selected enhancers or in enhancers transitioning from a poised to active state would represent binding sites for the responsible TFs and suggest possible upstream signaling pathways (Figure 4). After Kupffer cell depletion, monocytes adhering to the sinusoidal endothelium exhibited rapid changes in histone acetylation at poised enhancers in the vicinity of Kupffer cell lineage-determining factors, including LXRα (Sakai et al., 2019). In addition to binding sites for general macrophage lineage-determining factors, these enhancers were enriched for DNA recognition motifs for RBPJ and SMADs, which are downstream of Notch and TGF/BMP signaling pathways, respectively. Consistent with that, the Notch ligand DLL4 and TGF-β were found to be expressed by sinusoidal endothelial cells and to be capable of inducing LXRα expression in monocytes in vitro. The initial induction of Kupffer cell lineage-determining factors via activation of a poised enhancer landscape in recruited monocytes was followed by generation of new regions of open chromatin that gained histone acetylation in the vicinity of Kupffer cell identity genes, such as Clec4f (Figure 3B). These enhancers had enrichment for recognition motifs of general macrophage lineage-determining factors and the RBPJ and SMAD motifs but, in addition, also had motifs for Kupffer cell lineage-determining factors, including LXR and MAF family members. Motifs for NF-κB were also highly enriched, suggesting activation of TLRs by gut-derived endotoxins. Kupffer cell deletion of LXRα resulted in the loss of a significant fraction of the Kupffer-cell-specific gene expression as well as corresponding loss of a subset of Kupffer-cell-specific regions of open chromatin and histone H3K27ac, consistent with it functioning as a lineage-determining factor that drives enhancer selection in collaboration with core macrophage lineage-determining TFs, such as PU.1. In concert, these findings provided evidence that the potential of circulating monocytes to acquire the features of resident macrophage

populations is encoded in a pre-existing, poised enhancer landscape that is capable of being activated by tissue-specific signals (Sakai et al., 2019).

Effect of disease on resident and recruited macrophages

Although the diverse functions of resident and recruited macrophages normally have adaptive roles in development, immunity, and tissue homeostasis, many of these same functions exert pathogenic effects in a broad spectrum of human diseases (Tabas and Glass, 2013; Wynn et al., 2013). Examples include the roles of macrophages in development and clinical complications of atherosclerosis, obesity, nonalcoholic steatohepatitis, and Alzheimer disease (AD). Each of these diseases exhibits both overlapping and distinct features of chronic inflammation and varying combinations of immune cells that include tissue-resident and recruited macrophages. In contrast to acute injury or infection, in which the functions of macrophages and other immune cell types contribute to resolution and restoration of tissue homeostasis, many chronic diseases are associated with continuous generation of signals that provoke persistent immune cell inflammatory responses. For example, the development of atherosclerosis is driven by oxidatively modified lipoproteins within the artery wall that are ligands for macrophages and result in foam cell formation (Que et al., 2018). Haploinsufficiency in *Csf1*, the major ligand for the Csf1 receptor outside of the brain, results in near-complete resistance to atherosclerosis in mouse models (Rajavashisth et al., 1998; Smith et al., 1995), establishing an essential role for Csf1-dependent macrophages. Excess nutrient intake resulting in pathologic enlargement and death of adipocytes promotes macrophage accumulation in adipose tissue and the development of insulin resistance (Lee and Olefsky, 2021). Corresponding excess nutrient intake resulting in accumulation of triglyceride in the liver leads to recruitment of monocyte-derived macrophages and initiation of nonalcoholic steatohepatitis (NASH) (Ju and Tacke, 2016). Genetic or pharmacologic reduction of monocyte-derived macrophage accumulation in adipose tissue and liver ameliorates diet-induced disease (Huh et al., 2018; Mulder et al., 2017; Parker et al., 2018; Sullivan et al., 2013; Weisberg et al., 2006). Plaques of beta amyloid and tangles of hyperphosphorylated forms of tau in the brain are drivers of altered microglia phenotypes in AD (Wang and Colonna, 2019). In contrast to the examples provided by atherosclerosis, insulin resistance, and NASH, AD does not appear to be associated with recruitment of monocyte-derived cells. Genetic evidence (Bellenguez et al., 2020), as described in further detail below, suggests that microglia have essential roles in neuronal dysfunction and ultimate loss in AD.

These examples, as well as many others not discussed, linked tissue macrophages as active participants in many diseases, prompting heightened research directed toward understanding their mechanistic involvement. The concept that macrophages could be functionally classified into dichotomous phenotypes referred to as M1 (classically activated) or M2 (alternatively activated) was initially proposed more than 20 years ago, based on differential LPS responses of macrophages derived from mice exhibiting Th1 or Th2 lymphocyte biases (Mills et al., 2000). Macrophages from prototypical Th1 strains (C57BL/6, B10D2) were

more easily activated to produce NO with either IFN-γ or LPS than were macrophages from Th2 strains (BALB/c, DBA/2). In contrast, LPS stimulated macrophages from Th2, but not Th1, strains to increase arginine metabolism to ornithine. This paradigm was subsequently expanded and broadly applied to contrast macrophage phenotypes associated with chronic inflammatory disease (primarily M1) from those associated with tissue repair and tumor-associated macrophages (M2). However, the progressive discovery of signaling molecules recognized by macrophages, the development of improved methods for tracing and isolation of immune cells from tissues, and advances in genome-wide transcriptome analysis has generally revealed only limited resemblance of disease-associated macrophages to classical M1 or M2 phenotypes (Martinez and Gordon, 2014; Nahrendorf and Swirski, 2016).

DAMs, LAMs, and SAMs

The appreciation of myeloid cell heterogeneity under homeostatic and disease conditions has been significantly expanded by high-dimensional flow cytometry, and more recently mass cytometry and single-cell RNA-sequencing (scRNA-seq) methods, which enabled recognition of disease-associated macrophage phenotypes that were not readily apparent from RNA-seq of bulk populations. Examples include studies of microglia diversity in the brain (Keren-Shaul et al., 2017; Masuda et al., 2019) and myeloid cell diversity in the liver (Ramachandran et al., 2019; Seidman et al., 2020), lung (Sajti et al., 2020), and various tumor contexts (Pombo Antunes et al., 2021; Zilionis et al., 2019). Here, we consider disease-associated microglia (DAMs) in the brain, lipid-associated macrophages (LAMs) in adipose tissue, and scar-associated macrophages (SAMs) in the liver as examples that illustrate similarities and differences in disease-associated macrophage phenotypes and highlight important knowledge gaps.

DAMs were identified by comparing scRNA-seq transcriptomes of immune cells in the brains of wild-type (WT) mice or in a mouse model of AD characterized by high levels of β amyloid (Keren-Shaul et al., 2017). An analogous microglia phenotype, termed MgND, was discovered through comparative analysis of mouse models of amyotrophic lateral sclerosis, multiple sclerosis, and AD (Krasemann et al., 2017). DAMs represented a small fraction of microglia derived from the β-amyloid model and exhibited a distinct pattern of gene expression, characterized by increased expression of ~400 genes, including *Trem2*. Histologically, DAMs were localized to regions of amyloid deposition and were of particular interest because loss-of-function mutations in *TREM2* had previously been genetically linked to increased risk of non-familial forms of AD in humans (Guerreiro et al., 2013; Jonsson et al., 2013). Further, knockout (KO) of *Trem2* in the mouse resulted in failure of microglia to cluster around β-amyloid plaques and an increase in the spread of amyloid deposits (Jay et al., 2017; Wang et al., 2015). Isolation of microglia from *Trem2* KO mice in the context of the amyloid model suggested that transition of homeostatic microglia to DAM microglia could be separated into an initial *Trem2*-independent phase and a subsequent *Trem2*-dependent phase (Keren-Shaul et al., 2017). Based on the increased risk for AD associated with the loss-of-function mutation of *Trem2* and the spread of

Molecular Cell
Review

amyloid plaques in brains of mice and humans with loss-of-function mutations, the DAM phenotype is considered to exert overall protective functions in AD. However, evaluation of *Trem2* deficiency in the context of the PS19 mouse model of tauopathy yielded a strikingly different result. Crossing *Trem2* KO mice to PS19 mice resulted in significantly reduced microgliosis in brain regions affected by tauopathy, including the hippocampus (Leyns et al., 2017). In addition, gene-expression analyses and immunostaining revealed microglial activation was significantly attenuated in *Trem2* KO/PS19 mice compared with PS19 mice, along with lower levels of inflammatory cytokines and astrogliosis. These findings suggest that the DAM phenotype associated with tauopathy is different from that associated with amyloid and/or that the consequences of Trem2 signaling are context dependent, being protective in the case of excessive β amyloid and pathogenic in the case of tauopathy. A potential resolution to this seemingly paradoxical result is a recent finding that Trem2 remains protective when both amyloid and tau pathology are present (Lee et al., 2021).

An important discovery linking macrophage accumulation to insulin resistance in the setting of obesity was the finding of increased macrophage gene expression in intact adipose tissue of obese mice, in comparison with lean mice, as determined by microarray analysis (Weisberg et al., 2003; Xu et al., 2003). This finding led to documentation of monocyte-derived macrophage recruitment into obese adipose tissue and their direct contribution to insulin resistance of adipocytes. A characteristic feature of obese adipose tissue associated with insulin resistance is the presence of "crown-like structures" consisting of monocyte-derived macrophages and other immune cells that surround apoptotic/necrotic adipocytes (Geng et al., 2021). Recent systematic profiling of immune cells in lean and obese adipose tissue by scRNA-seq analysis led to the findings that macrophages within crown-like structures expressed high levels of *Trem2* and exhibited numerous cytoplasmic lipid droplets (Jaitin et al., 2019). These so-called LAMs depended on Trem2 for localization to necrotic/apoptotic adipocytes. Remarkably, *Trem2* KO mice exhibited even larger adipocytes than normal and worsened glucose and lipid homeostasis after an obesity-inducing diet than that of WT mice. Based on these findings, the LAM phenotype is interpreted as protective in the context of obese adipose tissue.

A third example of scRNA-seq leading to identification of a previously unappreciated macrophage disease phenotype resulted from analysis of non-parenchymal cells of the liver in individuals with advanced cirrhosis in comparison with controls (Ramachandran et al., 2019). Cirrhosis was associated with significant changes in gene expression in myeloid cells, endothelial cells, and stellate cells. In contrast to mouse models of brain amyloid and obesity, in which disease-associated phenotypes were absent in control animals, the overall population structures of myeloid cells were similar in cirrhotic and control liver samples, but relative proportions exhibited substantial differences. The most significantly altered populations exhibited high levels of expression of *TREM2* and *CD9* and were found to reside on pathological collagen fibers that are characteristic of cirrhosis. These so-called SAMs were proposed to be profibrotic based on the ability of SAM-condi-

tioned media to promote collagen gene expression in stellate cells *in vitro*. *Trem2/Cd9*⁺ myeloid cells were also identified in mouse models of NASH driven by high fat feeding (Daemen et al., 2021; Hou et al., 2021; Remmerie et al., 2020; Seidman et al., 2020; Xiong et al., 2019). In these contexts, loss of *Trem2* was associated with greater body weight and adipose tissue mass, in agreement with studies of LAMs, and increased hepatic triglyceride content (Hou et al., 2021). Whether the Trem2/Cd9-high cells in these mouse models are more closely related to LAMs or SAMs will require further investigation. Molecular and histological analysis suggested that Trem2 signaling in Kupffer cells had a protective role in maintaining mitochondrial function in hepatocytes. Loss of Trem2 has also recently been reported to be associated with compromised recovery from liver damage (Coelho et al., 2021). Thus, as in the case of DAMs in the brain, Trem2⁺ disease-associated macrophages in the liver may have both protective and pathogenic roles dependent on species and/or disease context.

Collectively, the studies of DAMs, LAMs, and SAMs provide evidence that Trem2 has a significant role in sensing disease phenotypes and in driving phenotypic consequences. In each case, the phenotypes of DAMs, LAMs, and SAMs bear only limited relationships to classically defined M1 or M2 macrophages. In addition, these do not represent the only disease-associated macrophage or microglia phenotypes present in each context. For example, a disease-associated population of microglia distinct from DAMs has been identified that is characterized by lipid accumulation, defective phagocytosis, and production of high levels of reactive oxygen species (Marschallinger et al., 2020). As noted above, studies of WT versus *Trem2* KO DAMs in the amyloid model provide evidence for Trem2-dependent and Trem2-independent phases, indicating important contributions of additional sensing and signaling pathways. For example, recent studies indicate that microglia use TAM receptors, which signal through tyrosine kinase activity, to recognize and engulf amyloid (Huang et al., 2021). Of interest, DAMs, LAMs, and SAMs are associated with pathogenic features that can be at scales that are much larger than the adjacent microglia or macrophage. Amyloid plaques in the brain, apoptotic adipocytes in adipose tissue, and collagen scars in the liver, all exceed the size of substrates amenable to uptake by phagocytosis. This association raises the question of whether an aspect of the Trem2-dependent or Trem2-independent phenotypes of these cells includes activation of extracellular degradation mechanisms.

Despite these similarities, each type of disease-associated macrophage resides in a distinct environment. Further, DAMs presumably arise exclusively from embryonically derived microglia, whereas LAMs are proposed to be derived from infiltrating monocytes and SAMs from both resident and recruited macrophages. In concert with these differences, the genes that distinguish DAMs, LAMs, and SAMs from the major homeostatic populations of brain, adipose tissue, and liver macrophages are largely non-overlapping, despite being at least partially driven by Trem2 signaling. This can potentially be explained, at least,

in part, by the divergent regulatory landscapes that Trem2 signaling acts upon within each cell type, analogous to the differential effects of LPS on gene expression of endogenous microglia and engrafted brain macrophages derived from HPCs, as discussed above (Shemer et al., 2018). The identification of DAMs, LAMs, and SAMs in neurodegenerative disease, obesity, and cirrhosis, respectively, suggests that analogous, but similarly distinct, populations of macrophages will be identified in other disease contexts.

Three major knowledge gaps emerge with respect to Trem2 and disease-associated macrophages: (1) what are the mechanisms that induce Trem2 expression, (2) what are the ligands that induce Trem2 signaling, and (3) what are the signaling pathways and TFs that drive the downstream responses? (Figure 5A) The topic of Trem2 ligands has been addressed by a recent review (Kober and Brett, 2017). In brief, Trem2 is a pattern-recognition receptor that signals primarily through interaction with Dap12 (Tyropb) to activate Syk and PI3K (Deczkowska et al., 2020). Many ligands have been proposed, including a variety of lipid species, ApoE, amyloid, and proteoglycans. Deciphering the most relevant ligands in pathological tissue environments remains a major challenge. Here, we will consider recent findings based on epigenetic analyses that suggest mechanisms leading to *Trem2* expression and downstream transcriptional consequences.

Epigenetic changes associated with a SAM-like phenotype

The observation that Trem2 deficiency leads to a partial acquisition of the DAM phenotype in 5XFAD mouse model of AD indicates a Trem2-independent response of microglia to the accumulation of amyloid (Keren-Shaul et al., 2017). Time-course studies were not performed in this model, and it is, therefore, not clear when detection of an altered brain environment occurs. In the case of high-fat feeding, significant accumulation of LAMs (defined by Cd9 staining) was not observed until significant obesity had been achieved (longer than 6 weeks) (Jaitin et al., 2019). In a dietary mouse model of NASH, it was possible to trace both the changes in gene expression in resident Kupffer cells and in monocyte-derived cells that localized to the sinusoidal niche (Seidman et al., 2020). These cells acquired a convergent pattern of gene expression that included upregulation of *Trem2*, *Cd9*, and other markers of both LAM and SAM phenotypes. Although significant changes in gene expression were observed between 1 and 4 weeks of the NASH-inducing diet, upregulation of Trem2 did not occur in the resident Kupffer cell population until after 10 weeks, ultimately reaching levels of expression >10-fold higher than in resident Kupffer cells in the healthy liver. Collectively, these results from the obesity and NASH models suggest that the upregulation of *Trem2* is driven by responses to emergent tissue pathology (i.e., adipocyte necrosis/apoptosis and liver inflammation, respectively) rather than the pathogenic diets themselves.

Direct comparison of the epigenetic landscapes of resident Kupffer cells of the healthy and NASH livers revealed that more than 4,000 regions of open chromatin showed >2-fold increases in H3K27ac, whereas ~3,400 regions exhibited

Figure 5. Inference of transcription factors driving changes in macrophage phenotypes in disease
(A) Temporal sequence of events in which resident or recruited macrophages sense disease-associated signals, leading to induction of Trem2 and other Trem2-independent genets. Expression of Trem2 enables additional sensing of disease-associated signals and regulation of downstream gene expression, presumably through Syk/PI3K-dependent mechanisms. Trem2-independent and Trem2-dependent gene expression contributes to generation of disease-associated macrophage phenotypes, exemplified by DAMs, LAMs, and SAMs.
(B) Inference of transcription factors associated with transition of Kupffer cells to a "SAM-like" phenotype in a mouse model of NASH. A NASH-inducing diet results in gain of H3K27ac at >4,000 enhancers and loss of H3K27ac at >3,500 enhancers. These changes are associated with upregulation of Trem2 and other LAM/SAM genes and downregulation of Kupffer cell identity genes. Motifs associated with gained H3K27ac include AP1/ATF, NFAT, RUNX, and EGR motifs.
(C) NASH-induced changes in Trem2-associated enhancers are shown. Genome browser tracks for Kupffer cell ATAC-seq, H3K27ac, ATF3, and LXR are illustrated under control and NASH conditions near the Trem2 gene. The NASH diet leads to marked increases in ATF3 and LXR binding, which is correlated with selection of a 3′ downstream, NASH-specific enhancer and increased H3K27ac at the Trem2 promoter, a poised intronic enhancer, and the NASH-induced 3′ enhancer.

Molecular Cell
Review

CellPress

>2-fold decreases (Figure 5B). As expected, putative enhancers exhibiting gained H3K27ac were associated with increases in gene expression associated with the SAM phenotype, whereas enhancers exhibiting loss of H3K27ac primarily occurred at Kupffer-cell-specific enhancers and were associated with an attenuation of Kupffer cell identity. An example is provided by the Trem2 gene, which exhibits an open promoter and a putative poised enhancer within intron 1 in homeostatic Kupffer cells (Figure 5C). After 20 weeks of the NASH-inducing diet, both of these regions exhibit significant increases in H3K27ac, consistent with gene activation. In addition, a region downstream of Trem2 exhibits a NASH-diet-specific ATAC-seq peak and H3K27ac, consistent with a NASH-specific enhancer. Of interest, a similar organization of regulatory elements is observed in mouse and human microglia.

Motif enrichment analysis of the ~4,000 Kupffer cell genomic regions gaining H3K27ac in the context of the NASH diet yielded highly significant enrichment for ATF3, NFAT, and Egr2 motifs, among others (Figure 5B). The NFAT motif is of interest because NFAT TFs are regulated by calcium signaling and have been suggested to be downstream of Trem2, based on the use of an NFAT reporter assay (Wang et al., 2015). ATF3 and Egr2 are of interest because their expression in response to the NASH diet begins to increase before upregulation of Trem2, suggesting possible roles in its induction. Atf3 is one of the most highly induced TFs by the NASH diet, and ChIP-seq experiments suggest it has a major role in driving the selection and activation of NASH enhancers, in part by repurposing LXRα from a Kupffer cell lineage-determining factor to an activator of a subset of genes associated with the SAM phenotype. Notably, both LXR and ATF3 binding are highly induced at Trem2 regulatory elements (Figure 5C). In concert, alterations in the enhancer landscapes of control and NASH Kupffer cells provide evidence that ATF3 and Egr2 function upstream and/or downstream of Trem2 in driving disease-associated macrophage phenotypes (Seidman et al., 2020).

SUMMARY AND FUTURE DIRECTIONS

Advances in single-cell sequencing technologies have revealed striking heterogeneity of macrophages in healthy and diseased tissues. The recent ability to quantitatively image hundreds to thousands of specific RNAs at a cellular resolution in tissue samples heralds the coming age of spatial transcriptomics; in which, gene expression patterns of contiguous cells can be examined in depth (Eng et al., 2019; Moffitt et al., 2018). Although these studies will enable unprecedented analysis of intercellular communication, the extent to which these methods will reveal as yet unappreciated cellular phenotypes remain to be discovered. Regardless, major questions for future studies include defining the functions of specific macrophage subsets, determining the mechanisms responsible for their diversification, and establishing whether those mechanisms provide potential sites of intervention in disease. As elaborated above, recent studies support a model in which hematopoietic progenitor cells and circulating monocytes have the potential to differentiate into tissue-distinct macrophage subtypes based on combinations of environment-specific signals that act on poised enhancer landscapes. In this model, such signals lead to rapid activation of poised enhancers that directly activate subset-specific lineage-determining TFs, exemplified by LXRα in Kupffer cells. These factors, in turn, collaborate with general macrophage-lineage-determining TFs resulting in the selection of new enhancers that permit further sensing of environmental signals and drive context-specific patterns of gene expression associated with cell-fate transitions. Experimental strategies that are based on depletion of resident macrophages, followed by repopulation with hematopoietic-derived precursors, provide powerful approaches for defining dynamic enhancer landscapes and inferring corresponding TFs. A corresponding strategy can also enable inference of TFs driving disease-associated macrophage phenotypes, representing potentially reversible alterations in cell "state."

In parallel with advances in single-cell sequencing, substantial progress is being made in single-cell analysis of open chromatin using scATAC-seq (Granja et al., 2021). This methodology has been demonstrated to be a powerful approach for identifying the open chromatin landscapes of distinct cell populations within complex tissues. Motif-enrichment analysis of open chromatin within clustered cells enables inference of key lineage-determining factors. Further, correlation analysis methods enable *in silico* estimations of likely enhancer-promoter interactions. This methodology, thus, has substantial promise for advancing mechanistic understanding of myeloid cell heterogeneity. Importantly, recent application of scATAC-seq to human brain samples enabled clustering of brain cell types based on patterns of open chromatin (Corces et al., 2020). Cell-specific patterns of open chromatin could be assembled from clustered cells, revealing enrichment of AD risk variants in putative microglia-specific regulatory elements. Limitations of scATAC at present include data sparsity and the inability to distinguish between poised and active regulatory landscapes. As illustrated by Kupffer cells in the healthy, versus NASH, liver, changes in activity states were more numerous than in open chromatin, providing greater power for motif-enrichment analysis (Seidman et al., 2020).

The computational advantages of simultaneous measurement of open chromatin and activity as measured by ATAC-seq and ChIP-seq of bulk cell populations are opposed by technical requirements for isolation of a sufficient number of the particular cell type of interest. Improvements in the sensitivities of assays that provide surrogates of enhancer activity, e.g., "cut and run" assays of histone modifications (Meers et al., 2019) and kethoxal-assisted single-strand sequencing (KAS-seq) assays (Wu et al., 2020) of single-stranded DNA associated with enhancer and promoter transcription bubbles, suggest that enhancer activity states can be effectively quantified using ~10,000 cells. Cell sorting informed by population-specific markers revealed by scRNA-seq analysis provides the usual starting point for isolation of specific cell types of interest. In addition, recent studies document the power of sorting nuclei according to cell of origin as another starting point for epigenetic analysis (Fullard et al., 2017; Mo et al., 2015). This can be accomplished in a highly cell-specific manner in

the mouse through the development of lineage-tracing reporters that are localized to the nucleus (Sakai et al., 2019; Seidman et al., 2020). It is also possible to sort nuclei using combinations of cell-specific markers that include nuclear envelop proteins (e.g., NeuN in neurons) and cell-specific TFs (e.g., PU.1 for microglia). An advantage of this methodology is that it can be applied to freshly frozen human tissues (Corces et al., 2017). This approach was recently used to define enhancer landscapes in microglia, astrocytes, oligodendrocytes, and neurons of the human cerebral cortex (Nott et al., 2019). In principle, each distinct cell state should be associated with a corresponding combination of TFs, which could be used as markers for nuclear isolation and epigenetic analysis.

As applied to microglia and macrophages isolated from human tissues, definition of dynamic enhancer landscapes in control and diseased tissues has the potential to not only provide insights into mechanisms driving myeloid cell fates and states but to also enable improved interpretation of natural genetic variation. Approximately 90% of the disease-risk alleles identified by genome-wide association studies are typically found to reside in non-coding regions of the genome, implicating effects on regulatory mechanisms. Enhancers have been clearly established to be sites of action of genetic variants, but, because enhancers are selected and function in cell-specific manner, interpretation requires atlases of these elements in relevant cell types under healthy and diseased conditions. As an example, risk alleles for AD were preferentially enriched in microglia enhancers, whereas risk alleles for psychiatric diseases were preferentially enriched in neurons (Nott et al., 2019). Distinguishing causal variants from passenger alleles in linkage disequilibrium remains a major challenge.

In addition to advances in technology, parallel progress in informatics approaches continue to enable deeper insights to be gleaned through integration of transcriptomic and epigenetic data at multiple scales. The central objective in leveraging dynamic enhancer landscapes to infer mechanisms driving changes in cell fate or state is to extract motifs that are bound by the corresponding TFs and, presumably, mediate enhancer selection and function. A limitation of these approaches is that motifs are discovered based on an enrichment in target over background sequences, and they do not provide insight into the importance of a particular motif in a particular enhancer. The recent development of machine-learning approaches that can be trained to recognize active enhancers and are amenable to interpretation are beginning to enable estimation of the importance of specific sequences within individual enhancers at base pair resolution (Libbrecht and Noble, 2015; Zhou and Troyanskaya, 2015). These methods appear promising for development of hypotheses regarding the roles of specific TFs at subsets of functionally coordinated enhancers, how such TFs interact to regulate enhancer function, and how these processes are affected by noncoding genetic variants.

Lastly, advances in the ability to reprogram iPSCs into various macrophage and microglia phenotypes are in early stages, but these efforts exhibit substantial potential to enable insights into a broad range of questions in human cells. Recent application of CRISPR interference (CRISPRi) screens to iPSC-derived microglia uncovered genes controlling microglia survival, activation, and phagocytosis, including neurodegeneration-associated genes (Dräger et al., 2021). The limitations of *in vitro* studies can be mitigated by more-complex systems, such as engraftment of organoids or humanized mice, as described previously (Hasselmann et al., 2019). For example, by combining transcriptomic and functional analyses with a chimeric AD mouse model, TREM2 deletion from iPSC-derived microglia was found to reduce survival, impair phagocytosis of key substrates, including APOE, and inhibit SDF-1α/CXCR4-mediated chemotaxis, culminating in an impaired response to β-amyloid plaques *in vivo* (McQuade et al., 2020). Importantly, these approaches also enable epigenetic studies that are very difficult to perform in human subjects.

In conclusion, the expanded recognition of macrophage diversity in normal and diseased tissues has revealed corresponding gaps in knowledge about underlying mechanisms and cellular functions. The systematic analysis of the dynamic regulatory landscapes of these cells *in vivo* is now becoming feasible, in concert with the availability of increasingly sophisticated methods of analysis. It should, thus, be possible in the near future to make rapid progress in defining many of the key TFs and upstream signaling pathways that establish specific macrophage phenotypes in health and disease. This knowledge is likely to contribute to the goal of defining pathogenic or protective roles of such pathways and the development of new therapeutic approaches for the broad spectrum of diseases in which macrophages have roles.

DECLARATION OF INTERESTS

C.K.G. is a co-founder and member of the scientific advisory board of Asteroid Therapeutics. T.D.T. and E.K. declare no competing interests.

REFERENCES

Abud, E.M., Ramirez, R.N., Martinez, E.S., Healy, L.M., Nguyen, C.H.H., Newman, S.A., Yeromin, A.V., Scarfone, V.M., Marsh, S.E., Fimbres, C., et al. (2017). iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94, 278–293.e9.

Adelman, K., Kennedy, M.A., Nechaev, S., Gilchrist, D.A., Muse, G.W., Chinenov, Y., and Rogatsky, I. (2009). Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling. Proc. Natl. Acad. Sci. USA 106, 18207–18212.

Bandura, D.R., Baranov, V.I., Ornatsky, O.I., Antonov, A., Kinach, R., Lou, X., Pavlov, S., Vorobiev, S., Dick, J.E., and Tanner, S.D. (2009). Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81, 6813–6822.

Barish, G.D., Yu, R.T., Karunasiri, M., Ocampo, C.B., Dixon, J., Benner, C., Dent, A.L., Tangirala, R.K., and Evans, R.M. (2010). Bcl-6 and NF-kappaB

Molecular Cell
Review

CellPress

cistromes mediate opposing regulation of the innate immune response. Genes Dev. *24*, 2760–2765.

Bartels, T., De Schepper, S., and Hong, S. (2020). Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science *370*, 66–69.

Bassler, K., Schulte-Schrepping, J., Warnat-Herresthal, S., Aschenbrenner, A.C., and Schultze, J.L. (2019). The Myeloid Cell Compartment-Cell by Cell. Annu. Rev. Immunol. *37*, 269–293.

Becher, B., Schlitzer, A., Chen, J., Mair, F., Sumatoh, H.R., Teng, K.W., Low, D., Ruedl, C., Riccardi-Castagnoli, P., Poidinger, M., et al. (2014). High-dimensional analysis of the murine myeloid cell system. Nat. Immunol. *15*, 1181–1189.

Bellenguez, C., Grenier-Boley, B., and Lambert, J.C. (2020). Genetics of Alzheimer's disease: where we are, and where we are going. Curr. Opin. Neurobiol. *61*, 40–48.

Bennett, M.L., and Bennett, F.C. (2020). The influence of environment and origin on brain resident macrophages and implications for therapy. Nat. Neurosci. *23*, 157–166.

Bennett, F.C., Bennett, M.L., Yaqoob, F., Mulinyawe, S.B., Grant, G.A., Hayden Gephart, M., Plowey, E.D., and Barres, B.A. (2018). A Combination of Ontogeny and CNS Environment Establishes Microglial Identity. Neuron *98*, 1170–1183.e8.

Bonfield, T.L., Raychaudhuri, B., Malur, A., Abraham, S., Trapnell, B.C., Kavuru, M.S., and Thomassen, M.J. (2003). PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am. J. Physiol. Lung Cell. Mol. Physiol. *285*, L1132–L1136.

Bonnardel, J., T'Jonck, W., Gaublomme, D., Browaeys, R., Scott, C.L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S.A., Kremer, A., et al. (2019). Stellate cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on monocytes colonizing the liver macrophage niche. Immunity *51*, 638–654.e9.

Browaeys, R., Saelens, W., and Saeys, Y. (2020). NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods *17*, 159–162.

Buenrostro, J.D., Wu, B., Chang, H.Y., and Greenleaf, W.J. (2015). ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr. Protoc. Mol. Biol. *109*, 21.29.1–21.29.9.

Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. (2014). Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. *17*, 131–143.

Buttgereit, A., Lelios, I., Yu, X., Vrohlings, M., Krakoski, N.R., Gautier, E.L., Nishinakamura, R., Becher, B., and Greter, M. (2016). Sall1 is a transcriptional regulator defining microglia identity and function. Nat. Immunol. *17*, 1397–1406.

Coelho, I., Duarte, N., Barros, A., Macedo, M.P., and Penha-Gonçalves, C. (2021). Trem-2 promotes emergence of restorative macrophages and endothelial cells during recovery from hepatic tissue damage. Front. Immunol. *11*, 616044.

Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong, N.A., Vesuna, S., Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., et al. (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods *14*, 959–962.

Corces, M.R., Shcherbina, A., Kundu, S., Gloudemans, M.J., Frésard, L., Granja, J.M., Louie, B.H., Eulalio, T., Shams, S., Bagdatli, S.T., et al. (2020). Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases. Nat. Genet. *52*, 1158–1168.

Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al. (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA *107*, 21931–21936.

Cronk, J.C., Filiano, A.J., Louveau, A., Marin, I., Marsh, R., Ji, E., Goldman, D.H., Smirnov, I., Geraci, N., Acton, S., et al. (2018). Peripherally derived macrophages engraft the brain independent of irradiation and maintain an identity distinct from microglia. J. Exp. Med. *215*, 1627–1647.

Cuartero, S., Weiss, F.D., Dharmalingam, G., Guo, Y., Ing-Simmons, E., Masella, S., Robles-Rebollo, I., Xiao, X., Wang, Y.F., Barozzi, I., et al. (2018). Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation. Nat. Immunol. *19*, 932–941.

Daemen, S., Gainullina, A., Kalugotla, G., He, L., Chan, M.M., Beals, J.W., Liss, K.H., Klein, S., Feldstein, A.E., Finck, B.N., et al. (2021). Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. *34*, 108626.

David, B.A., Rezende, R.M., Antunes, M.M., Santos, M.M., Freitas Lopes, M.A., Diniz, A.B., Sousa Pereira, R.V., Marchesi, S.C., Alvarenga, D.M., Nakagaki, B.N., et al. (2016). Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice. Gastroenterology *151*, 1176–1191.

De Santa, F., Narang, V., Yap, Z.H., Tusi, B.K., Burgold, T., Austenaa, L., Bucci, G., Caganova, M., Notarbartolo, S., Casola, S., et al. (2009). Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. *28*, 3341–3352.

Deczkowska, A., Weiner, A., and Amit, I. (2020). The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell *181*, 1207–1217.

Dey, A., Yang, W., Gegonne, A., Nishiyama, A., Pan, R., Yagi, R., Grinberg, A., Finkelman, F.D., Pfeifer, K., Zhu, J., et al. (2019). BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses. EMBO J. *38*, e100293.

Dräger, N.M., Sattler, S.M., Huang, C.T.-L., Teter, O.M., Leng, K., Hashemi, S.H., Hong, J., Clelland, C.D., Zhan, L., Kodama, L., et al. (2021). A CRISPRi/a platform in iPSC-derived microglia uncovers regulators of disease states. bioRxiv, 2021.2006.2016.448639.

Eng, C.L., Lawson, M., Zhu, Q., Dries, R., Koulena, N., Takei, Y., Yun, J., Cronin, C., Karp, C., Yuan, G.C., and Cai, L. (2019). Transcriptome-scale superresolved imaging in tissues by RNA seqFISH. Nature *568*, 235–239.

Epelman, S., Lavine, K.J., Beaudin, A.E., Sojka, D.K., Carrero, J.A., Calderon, B., Brija, T., Gautier, E.L., Ivanov, S., Satpathy, A.T., et al. (2014). Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity *40*, 91–104.

Fisher, R.C., and Scott, E.W. (1998). Role of PU.1 in hematopoiesis. Stem Cells *16*, 25–37.

Fonseca, G.J., Tao, J., Westin, E.M., Duttke, S.H., Spann, N.J., Strid, T., Shen, Z., Stender, J.D., Sakai, M., Link, V.M., et al. (2019). Diverse motif ensembles specify non-redundant DNA binding activities of AP-1 family members in macrophages. Nat. Commun. *10*, 414.

Fullard, J.F., Giambartolomei, C., Hauberg, M.E., Xu, K., Voloudakis, G., Shao, Z., Bare, C., Dudley, J.T., Mattheisen, M., Robakis, N.K., et al. (2017). Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Hum. Mol. Genet. *26*, 1942–1951.

Furlong, E.E.M., and Levine, M. (2018). Developmental enhancers and chromosome topology. Science *361*, 1341–1345.

Gatchalian, J., Liao, J., Maxwell, M.B., and Hargreaves, D.C. (2020). Control of stimulus-dependent responses in macrophages by SWI/SNF chromatin remodeling complexes. Trends Immunol. *41*, 126–140.

Gautier, E.L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K.G., Gordonov, S., et al.; Immunological Genome Consortium (2012). Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. *13*, 1118–1128.

Geng, J., Zhang, X., Prabhu, S., Shahoei, S.H., Nelson, E.R., Swanson, K.S., Anastasio, M.A., and Smith, A.M. (2021). 3D microscopy and deep learning reveal the heterogeneity of crown-like structure microenvironments in intact adipose tissue. Sci. Adv. *7*, eabe2480.

Ghisletti, S., Barozzi, I., Mietton, F., Polletti, S., De Santa, F., Venturini, E., Gregory, L., Lonie, L., Chew, A., Wei, C.L., et al. (2010). Identification and

characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 32, 317–328.

Giladi, A., and Amit, I. (2018). Single-cell genomics: a stepping stone for future immunology discoveries. Cell 172, 14–21.

Gilchrist, D.A., Dos Santos, G., Fargo, D.C., Xie, B., Gao, Y., Li, L., and Adelman, K. (2010). Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. Cell 143, 540–551.

Ginhoux, F., and Guilliams, M. (2016). Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439–449.

Glass, C.K., and Natoli, G. (2016). Molecular control of activation and priming in macrophages. Nat. Immunol. 17, 26–33.

Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., Garner, H., Trouillet, C., de Bruijn, M.F., Geissmann, F., and Rodewald, H.R. (2015). Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551.

Gosselin, D., Link, V.M., Romanoski, C.E., Fonseca, G.J., Eichenfield, D.Z., Spann, N.J., Stender, J.D., Chun, H.B., Garner, H., Geissmann, F., and Glass, C.K. (2014). Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327–1340.

Gosselin, D., Skola, D., Coufal, N.G., Holtman, I.R., Schlachetzki, J.C.M., Sajti, E., Jaeger, B.N., O'Connor, C., Fitzpatrick, C., Pasillas, M.P., et al. (2017). An environment-dependent transcriptional network specifies human microglia identity. Science 356, eaal3222.

Granja, J.M., Corces, M.R., Pierce, S.E., Bagdatli, S.T., Choudhry, H., Chang, H.Y., and Greenleaf, W.J. (2021). ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet. 53, 403–411.

Grindberg, R.V., Yee-Greenbaum, J.L., McConnell, M.J., Novotny, M., O'Shaughnessy, A.L., Lambert, G.M., Araúzo-Bravo, M.J., Lee, J., Fishman, M., Robbins, G.E., et al. (2013). RNA-sequencing from single nuclei. Proc. Natl. Acad. Sci. USA 110, 19802–19807.

Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., et al.; Alzheimer Genetic Analysis Group (2013). TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117–127.

Gupte, R., Muse, G.W., Chinenov, Y., Adelman, K., and Rogatsky, I. (2013). Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc. Natl. Acad. Sci. USA 110, 14616–14621.

Hah, N., Benner, C., Chong, L.W., Yu, R.T., Downes, M., and Evans, R.M. (2015). Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Proc. Natl. Acad. Sci. USA 112, E297–E302.

Hammond, T.R., Robinton, D., and Stevens, B. (2018). Microglia and the brain: complementary partners in development and disease. Annu. Rev. Cell Dev. Biol. 34, 523–544.

Hammond, T.R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A.J., Gergits, F., Segel, M., Nemesh, J., et al. (2019). Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity 50, 253–271.e6.

Hargreaves, D.C., Horng, T., and Medzhitov, R. (2009). Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129–145.

Hasselmann, J., Coburn, M.A., England, W., Figueroa Velez, D.X., Kiani Shabestari, S., Tu, C.H., McQuade, A., Kolahdouzan, M., Echeverria, K., Claes, C., et al. (2019). Development of a chimeric model to study and manipulate human microglia in vivo. Neuron 103, 1016–1033.e10.

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining TFs prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589.

Heinz, S., Romanoski, C.E., Benner, C., Allison, K.A., Kaikkonen, M.U., Orozco, L.D., and Glass, C.K. (2013). Effect of natural genetic variation on enhancer selection and function. Nature 503, 487–492.

Hickman, S.E., Kingery, N.D., Ohsumi, T.K., Borowsky, M.L., Wang, L.C., Means, T.K., and El Khoury, J. (2013). The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896–1905.

Hou, J., Zhang, J., Cui, P., Zhou, Y., Liu, C., Wu, X., Ji, Y., Wang, S., Cheng, B., Ye, H., et al. (2021). TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J. Clin. Invest. 131, e135197.

Huang, Y., Happonen, K.E., Burrola, P.G., O'Connor, C., Hah, N., Huang, L., Nimmerjahn, A., and Lemke, G. (2021). Microglia use TAM receptors to detect and engulf amyloid β plaques. Nat. Immunol. 22, 586–594.

Huh, J.H., Kim, H.M., Lee, E.S., Kwon, M.H., Lee, B.R., Ko, H.J., and Chung, C.H. (2018). Dual CCR2/5 antagonist attenuates obesity-induced insulin resistance by regulating macrophage recruitment and M1/M2 status. Obesity (Silver Spring) 26, 378–386.

Jaitin, D.A., Adlung, L., Thaiss, C.A., Weiner, A., Li, B., Descamps, H., Lundgren, P., Bleriot, C., Liu, Z., Deczkowska, A., et al. (2019). Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686–698.e14.

Jay, T.R., Hirsch, A.M., Broihier, M.L., Miller, C.M., Neilson, L.E., Ransohoff, R.M., Lamb, B.T., and Landreth, G.E. (2017). Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J. Neurosci. 37, 637–647.

Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107–116.

Ju, C., and Tacke, F. (2016). Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell. Mol. Immunol. 13, 316–327.

Kaikkonen, M.U., Spann, N.J., Heinz, S., Romanoski, C.E., Allison, K.A., Stender, J.D., Chun, H.B., Tough, D.F., Prinjha, R.K., Benner, C., and Glass, C.K. (2013). Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51, 310–325.

Kawai, T., and Akira, S. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637–650.

Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017). A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169, 1276–1290.e17.

Kober, D.L., and Brett, T.J. (2017). TREM2-ligand interactions in health and disease. J. Mol. Biol. 429, 1607–1629.

Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O'Loughlin, E., Xu, Y., Fanek, Z., et al. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581.e9.

Krenkel, O., and Tacke, F. (2017). Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17, 306–321.

Lai, D., Wan, M., Wu, J., Preston-Hurlburt, P., Kushwaha, R., Grundström, T., Imbalzano, A.N., and Chi, T. (2009). Induction of TLR4-target genes entails calcium/calmodulin-dependent regulation of chromatin remodeling. Proc. Natl. Acad. Sci. USA 106, 1169–1174.

Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., Jung, S., and Amit, I. (2014). Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326.

Lawrence, T., and Natoli, G. (2011). Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11, 750–761.

Lee, Y.S., and Olefsky, J. (2021). Chronic tissue inflammation and metabolic disease. Genes Dev. 35, 307–328.

Lee, S.H., Meilandt, W.J., Xie, L., Gandham, V.D., Ngu, H., Barck, K.H., Rezzonico, M.G., Imperio, J., Lalehzadeh, G., Huntley, M.A., et al. (2021). Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Neuron 109, 1283–1301.e6.

CellPress

Levine, M. (2010). Transcriptional enhancers in animal development and evolution. Curr. Biol. 20, R754–R763.

Leyns, C.E.G., Ulrich, J.D., Finn, M.B., Stewart, F.R., Koscal, L.J., Remolina Serrano, J., Robinson, G.O., Anderson, E., Colonna, M., and Holtzman, D.M. (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. USA 114, 11524–11529.

Li, P., Spann, N.J., Kaikkonen, M.U., Lu, M., Oh, D.Y., Fox, J.N., Bandyopadhyay, G., Talukdar, S., Xu, J., Lagakos, W.S., et al. (2013). NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 155, 200–214.

Li, Q., Cheng, Z., Zhou, L., Darmanis, S., Neff, N.F., Okamoto, J., Gulati, G., Bennett, M.L., Sun, L.O., Clarke, L.E., et al. (2019). Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron 101, 207–223.e10.

Libbrecht, M.W., and Noble, W.S. (2015). Machine learning applications in genetics and genomics. Nat. Rev. Genet. 16, 321–332.

Link, V.M., Duttke, S.H., Chun, H.B., Holtman, I.R., Westin, E., Hoeksema, M.A., Abe, Y., Skola, D., Romanoski, C.E., Tao, J., et al. (2018). Analysis of genetically diverse macrophages reveals local and domain-wide mechanisms that control TF binding and function. Cell 173, 1796–1809.e1717.

Mancuso, R., Van Den Daele, J., Fattorelli, N., Wolfs, L., Balusu, S., Burton, O., Liston, A., Sierksma, A., Fourne, Y., Poovathingal, S., et al. (2019). Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat. Neurosci 22, 2111–2116.

Marschallinger, J., Iram, T., Zardeneta, M., Lee, S.E., Lehallier, B., Haney, M.S., Pluvinage, J.V., Mathur, V., Hahn, O., Morgens, D.W., et al. (2020). Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat. Neurosci. 23, 194–208.

Martinez, F.O., and Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13.

Mass, E., Ballesteros, I., Farlik, M., Halbritter, F., Günther, P., Crozet, L., Jacome-Galarza, C.E., Händler, K., Klughammer, J., Kobayashi, Y., et al. (2016). Specification of tissue-resident macrophages during organogenesis. Science 353, aaf4238.

Masuda, T., Sankowski, R., Staszewski, O., Böttcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S., Kunz, P., van Loo, G., et al. (2019). Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388–392.

Matcovitch-Natan, O., Winter, D.R., Giladi, A., Vargas Aguilar, S., Spinrad, A., Sarrazin, S., Ben-Yehuda, H., David, E., Zelada González, F., Perrin, P., et al. (2016). Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670.

McGrath, K.E., Frame, J.M., Fegan, K.H., Bowen, J.R., Conway, S.J., Catherman, S.C., Kingsley, P.D., Koniski, A.D., and Palis, J. (2015). Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Rep. 11, 1892–1904.

McQuade, A., Kang, Y.J., Hasselmann, J., Jairaman, A., Sotelo, A., Coburn, M., Shabestari, S.K., Chadarevian, J.P., Fote, G., Tu, C.H., et al. (2020). Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. Nat. Commun. 11, 5370.

Meers, M.P., Bryson, T.D., Henikoff, J.G., and Henikoff, S. (2019). Improved CUT&RUN chromatin profiling tools. eLife 8, e46314.

Mills, C.D., Kincaid, K., Alt, J.M., Heilman, M.J., and Hill, A.M. (2000). M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164, 6166–6173.

Mo, A., Mukamel, E.A., Davis, F.P., Luo, C., Henry, G.L., Picard, S., Urich, M.A., Nery, J.R., Sejnowski, T.J., Lister, R., et al. (2015). Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86, 1369–1384.

Moffitt, J.R., Bambah-Mukku, D., Eichhorn, S.W., Vaughn, E., Shekhar, K., Perez, J.D., Rubinstein, N.D., Hao, J., Regev, A., Dulac, C., and Zhuang, X. (2018). Molecular, spatial, and functional single-cell profiling of the hypothalamic preoptic region. Science 362, eaau5324.

Muffat, J., Li, Y., Yuan, B., Mitalipova, M., Omer, A., Corcoran, S., Bakiasi, G., Tsai, L.H., Aubourg, P., Ransohoff, R.M., and Jaenisch, R. (2016). Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 22, 1358–1367.

Mulder, P., van den Hoek, A.M., and Kleemann, R. (2017). The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. PLoS ONE 12, e0169740.

Murakami, K., Sasaki, H., Nishiyama, A., Kurotaki, D., Kawase, W., Ban, T., Nakabayashi, J., Kanzaki, S., Sekita, Y., Nakajima, H., et al. (2021). A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes. Nat. Immunol. 22, 301–311.

Nahrendorf, M., and Swirski, F.K. (2016). Abandoning M1/M2 for a network model of macrophage function. Circ. Res. 119, 414–417.

Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010). Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123.

Nott, A., Holtman, I.R., Coufal, N.G., Schlachetzki, J.C.M., Yu, M., Hu, R., Han, C.Z., Pena, M., Xiao, J., Wu, Y., et al. (2019). Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134–1139.

Okabe, Y., and Medzhitov, R. (2014). Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832–844.

Okabe, Y., and Medzhitov, R. (2016). Tissue biology perspective on macrophages. Nat. Immunol. 17, 9–17.

Orme, I.M., and Basaraba, R.J. (2014). The formation of the granuloma in tuberculosis infection. Semin. Immunol. 26, 601–609.

Parker, R., Weston, C.J., Miao, Z., Corbett, C., Armstrong, M.J., Ertl, L., Ebsworth, K., Walters, M.J., Baumart, T., Newland, D., et al. (2018). CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 314, G483–G493.

Pombo Antunes, A.R., Scheyltjens, I., Lodi, F., Messiaen, J., Antoranz, A., Duerinck, J., Kancheva, D., Martens, L., De Vlaminck, K., Van Hove, H., et al. (2021). Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595–610.

Prinz, M., Jung, S., and Priller, J. (2019). Microglia biology: one century of evolving concepts. Cell 179, 292–311.

Que, X., Hung, M.Y., Yeang, C., Gonen, A., Prohaska, T.A., Sun, X., Diehl, C., Määttä, A., Gaddis, D.E., Bowden, K., et al. (2018). Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558, 301–306.

Rajavashisth, T., Qiao, J.H., Tripathi, S., Tripathi, J., Mishra, N., Hua, M., Wang, X.P., Loussararian, A., Clinton, S., Libby, P., and Lusis, A. (1998). Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 101, 2702–2710.

Ramachandran, P., Dobie, R., Wilson-Kanamori, J.R., Dora, E.F., Henderson, B.E.P., Luu, N.T., Portman, J.R., Matchett, K.P., Brice, M., Marwick, J.A., et al. (2019). Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512–518.

Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020). Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity 53, 641–657.e14.

Sajti, E., Link, V.M., Ouyang, Z., Spann, N.J., Westin, E., Romanoski, C.E., Fonseca, G.J., Prince, L.S., and Glass, C.K. (2020). Transcriptomic and epigenetic mechanisms underlying myeloid diversity in the lung. Nat. Immunol. 21, 221–231.

Sakai, M., Troutman, T.D., Seidman, J.S., Ouyang, Z., Spann, N.J., Abe, Y., Ego, K.M., Bruni, C.M., Deng, Z., Schlachetzki, J.C.M., et al. (2019). Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity. Immunity 51, 655–670.e8.

Schulz, C., Gomez Perdiguero, E., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S.E.W., Pollard, J.W., et al. (2012). A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90.

Scott, C.L., Zheng, F., De Baetselier, P., Martens, L., Saeys, Y., De Prijck, S., Lippens, S., Abels, C., Schoonooghe, S., Raes, G., et al. (2016). Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat. Commun. 7, 10321.

Seeley, J.J., and Ghosh, S. (2017). Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 101, 107–119.

Seidman, J.S., Troutman, T.D., Sakai, M., Gola, A., Spann, N.J., Bennett, H., Bruni, C.M., Ouyang, Z., Li, R.Z., Sun, X., et al. (2020). Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity 52, 1057–1074.e7.

Shemer, A., Grozovski, J., Tay, T.L., Tao, J., Volaski, A., Süß, P., Ardura-Fabregat, A., Gross-Vered, M., Kim, J.S., David, E., et al. (2018). Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge. Nat. Commun. 9, 5206.

Smith, J.D., Trogan, E., Ginsberg, M., Grigaux, C., Tian, J., and Miyata, M. (1995). Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. USA 92, 8264–8268.

Soucie, E.L., Weng, Z., Geirsdóttir, L., Molawi, K., Maurizio, J., Fenouil, R., Mossadegh-Keller, N., Gimenez, G., VanHille, L., Beniazza, M., et al. (2016). Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cells. Science 351, aad5510.

Sullivan, T.J., Miao, Z., Zhao, B.N., Ertl, L.S., Wang, Y., Krasinski, A., Walters, M.J., Powers, J.P., Dairaghi, D.J., Baumgart, T., et al. (2013). Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62, 1623–1632.

Svoboda, D.S., Barrasa, M.I., Shu, J., Rietjens, R., Zhang, S., Mitalipova, M., Berube, P., Fu, D., Shultz, L.D., Bell, G.W., and Jaenisch, R. (2019). Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. Proc. Natl. Acad. Sci. USA 116, 25293–25303.

Tabas, I., and Glass, C.K. (2013). Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166–172.

Takeda, K., and Akira, S. (2004). TLR signaling pathways. Semin. Immunol. 16, 3–9.

Wang, S., and Colonna, M. (2019). Microglia in Alzheimer's disease: a target for immunotherapy. J. Leukoc. Biol. 106, 219–227.

Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061–1071.

Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808.

Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R.L., and Ferrante, A.W., Jr. (2006). CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116, 115–124.

Wen, Y., Lambrecht, J., Ju, C., and Tacke, F. (2021). Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell. Mol. Immunol. 18, 45–56.

Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., and Young, R.A. (2013). Master TFs and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319.

Wu, T., Lyu, R., You, Q., and He, C. (2020). Kethoxal-assisted single-stranded DNA sequencing captures global transcription dynamics and enhancer activity in situ. Nat. Methods 17, 515–523.

Wynn, T.A., Chawla, A., and Pollard, J.W. (2013). Macrophage biology in development, homeostasis and disease. Nature 496, 445–455.

Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.Y., Ji, Y., Li, C., Guo, L., et al. (2019). Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol. Cell 75, 644–660.e5.

Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821–1830.

Xu, Z., Rao, Y., Huang, Y., Zhou, T., Feng, R., Xiong, S., Yuan, T.F., Qin, S., Lu, Y., Zhou, X., et al. (2020). Efficient strategies for microglia replacement in the central nervous system. Cell Rep. 32, 108041.

Zaidi, Y., Aguilar, E.G., Troncoso, M., Ilatovskaya, D.V., and DeLeon-Pennell, K.Y. (2021). Immune regulation of cardiac fibrosis post myocardial infarction. Cell. Signal. 77, 109837.

Zhou, J., and Troyanskaya, O.G. (2015). Predicting effects of noncoding variants with deep learning-based sequence model. Nat. Methods 12, 931–934.

Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H.D., Krishnan, I., Maroni, G., Meyerovitz, C.V., Kerwin, C.M., et al. (2019). Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317–1334.e10.